Browse FARP2

Summary
SymbolFARP2
NameFERM, RhoGEF and pleckstrin domain protein 2
Aliases KIAA0793; PLEKHC3; FRG; FERM domain including RhoGEF; FGD1-related Cdc42-GEF; PH domain-containing family C ......
Chromosomal Location2q37.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location -
Domain PF08736 FERM adjacent (FA)
PF09380 FERM C-terminal PH-like domain
PF00373 FERM central domain
PF09379 FERM N-terminal domain
PF00169 PH domain
PF00621 RhoGEF domain
Function

Functions as guanine nucleotide exchange factor that activates RAC1. May have relatively low activity. Plays a role in the response to class 3 semaphorins and remodeling of the actin cytoskeleton. Plays a role in TNFSF11-mediated osteoclast differentiation, especially in podosome rearrangement and reorganization of the actin cytoskeleton. Regulates the activation of ITGB3, integrin signaling and cell adhesion (By similarity).

> Gene Ontology
 
Biological Process GO:0002521 leukocyte differentiation
GO:0002573 myeloid leukocyte differentiation
GO:0007265 Ras protein signal transduction
GO:0007266 Rho protein signal transduction
GO:0016322 neuron remodeling
GO:0016601 Rac protein signal transduction
GO:0021700 developmental maturation
GO:0030099 myeloid cell differentiation
GO:0030316 osteoclast differentiation
GO:0031532 actin cytoskeleton reorganization
GO:0033622 integrin activation
GO:0033623 regulation of integrin activation
GO:0035023 regulation of Rho protein signal transduction
GO:0042551 neuron maturation
GO:0043254 regulation of protein complex assembly
GO:0046578 regulation of Ras protein signal transduction
GO:0048469 cell maturation
GO:0051056 regulation of small GTPase mediated signal transduction
GO:0071526 semaphorin-plexin signaling pathway
GO:0071800 podosome assembly
Molecular Function GO:0005085 guanyl-nucleotide exchange factor activity
GO:0005088 Ras guanyl-nucleotide exchange factor activity
GO:0005089 Rho guanyl-nucleotide exchange factor activity
GO:0030676 Rac guanyl-nucleotide exchange factor activity
Cellular Component GO:0019898 extrinsic component of membrane
> KEGG and Reactome Pathway
 
KEGG hsa04015 Rap1 signaling pathway
hsa04520 Adherens junction
Reactome R-HSA-422475: Axon guidance
R-HSA-1266738: Developmental Biology
R-HSA-399955: SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion
R-HSA-373755: Semaphorin interactions
Summary
SymbolFARP2
NameFERM, RhoGEF and pleckstrin domain protein 2
Aliases KIAA0793; PLEKHC3; FRG; FERM domain including RhoGEF; FGD1-related Cdc42-GEF; PH domain-containing family C ......
Chromosomal Location2q37.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between FARP2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolFARP2
NameFERM, RhoGEF and pleckstrin domain protein 2
Aliases KIAA0793; PLEKHC3; FRG; FERM domain including RhoGEF; FGD1-related Cdc42-GEF; PH domain-containing family C ......
Chromosomal Location2q37.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of FARP2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolFARP2
NameFERM, RhoGEF and pleckstrin domain protein 2
Aliases KIAA0793; PLEKHC3; FRG; FERM domain including RhoGEF; FGD1-related Cdc42-GEF; PH domain-containing family C ......
Chromosomal Location2q37.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of FARP2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.8670.0321
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)651.1540.531
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.6640.607
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.1050.739
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.0790.968
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.1380.956
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.3310.322
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.6030.682
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.030.985
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.250.819
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.2330.403
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.0170.831
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of FARP2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277311.14.170.339
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 01407.1-7.11
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275911.13.47.70.176
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.1011.10.36
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47250250.364
1329033130MelanomaallAnti-PD-1 (nivolumab) 38275.305.30.507
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolFARP2
NameFERM, RhoGEF and pleckstrin domain protein 2
Aliases KIAA0793; PLEKHC3; FRG; FERM domain including RhoGEF; FGD1-related Cdc42-GEF; PH domain-containing family C ......
Chromosomal Location2q37.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of FARP2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolFARP2
NameFERM, RhoGEF and pleckstrin domain protein 2
Aliases KIAA0793; PLEKHC3; FRG; FERM domain including RhoGEF; FGD1-related Cdc42-GEF; PH domain-containing family C ......
Chromosomal Location2q37.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of FARP2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by FARP2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolFARP2
NameFERM, RhoGEF and pleckstrin domain protein 2
Aliases KIAA0793; PLEKHC3; FRG; FERM domain including RhoGEF; FGD1-related Cdc42-GEF; PH domain-containing family C ......
Chromosomal Location2q37.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of FARP2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolFARP2
NameFERM, RhoGEF and pleckstrin domain protein 2
Aliases KIAA0793; PLEKHC3; FRG; FERM domain including RhoGEF; FGD1-related Cdc42-GEF; PH domain-containing family C ......
Chromosomal Location2q37.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of FARP2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolFARP2
NameFERM, RhoGEF and pleckstrin domain protein 2
Aliases KIAA0793; PLEKHC3; FRG; FERM domain including RhoGEF; FGD1-related Cdc42-GEF; PH domain-containing family C ......
Chromosomal Location2q37.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between FARP2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolFARP2
NameFERM, RhoGEF and pleckstrin domain protein 2
Aliases KIAA0793; PLEKHC3; FRG; FERM domain including RhoGEF; FGD1-related Cdc42-GEF; PH domain-containing family C ......
Chromosomal Location2q37.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting FARP2 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.